摘要
目的 探讨程序性死亡受体1(PD-1)抑制剂治疗后非小细胞肺癌(NSCLC)患者发生甲状腺功能异常的影响因素。方法 选取64例接受PD-1抑制剂治疗的NSCLC患者,记录患者的临床资料,统计患者治疗后甲状腺功能异常发生情况,采用Logistic回归模型分析PD-1抑制剂治疗后NSCLC患者发生甲状腺功能异常的影响因素。结果 64例NSCLC患者经PD-1抑制剂治疗后,发生甲状腺功能异常22例(34.38%),其中甲亢5例,甲减12例,亚甲亢2例,亚甲减3例。多因素Logistic回归分析结果显示,女性、肥胖、病程≥6个月、有放疗史、有化疗史、基线甲状腺过氧化物酶抗体(TPO-Ab)阳性均是PD-1抑制剂治疗后NSCLC患者发生甲状腺功能异常的独立危险因素(P﹤0.05)。结论 女性、肥胖、病程≥6个月、有放疗史、有化疗史、基线TPO-Ab阳性均是PD-1抑制剂治疗后NSCLC患者发生甲状腺功能异常的独立危险因素,临床可据此制订针对性管理方案,积极对症干预,以降低甲状腺功能异常的发生率。
Objective To analyze the influencing factors of thyroid dysfunction in patients with non-small cell lung cancer(NSCLC)after programmed cell death 1(PD-1)inhibitor treatment.Method Sixty-four NSCLC patients who rev-eived PD-1 inhibitor treatment were selected,clinical data of the patients were recorded,and the occurrence of thyroid dysfunction after treatment was statistically analyzed.Logistic regression model was used to analyze the influencing fac-tors of thyroid dysfunction in NSCLC patients after PD-1 inhibitor treatment.Result Among 64 NSCLC patients treated with PD-1 inhibitor,22(34.38%)occurred thyroid dysfunction,including 5 hyperthyroidism,12 hypothyroidism,2 hypo-thyroidism,and 3 hypothyroidism.Multivariate Logistic regression analysis showed that female,obesity,disease dura-tion≥6 months,history of radiotherapy,history of chemotherapy,and positive thyroid peroxidase antibody(TPO-Ab)at baseline were independent risk factors for thyroid dysfunction in NSCLC patients after PD-1 inhibitor treatment(P<0.05).Conclusion Female,obesity,disease duration≥6 months,history of radiotherapy,history of chemotherapy,and positive TPO-Ab at baseline were independent risk factors for thyroid dysfunction in NSCLC patients after PD-1 inhibitor treatment.Therefore,targeted management programs can be formulated and symptomatic intervention can be actively per-formed to reduce the incidence of thyroid dysfunction.
作者
李丽芳
张萌
艾冬冬
刘小红
LI Lifang;ZHANG Meng;AI Dongdong;LIU Xiaohong(Department of Oncology,Xinyu People’s Hospital,Xinyu 338000,Jiangxi,China;Department of Endocrinology,Xinyu People’s Hospital,Xinyu 338000,Jiangxi,China;Department of Clinical Laboratory,Xinyu People’s Hospital,Xinyu 338000,Jiangxi,China)
出处
《癌症进展》
2024年第11期1242-1246,共5页
Oncology Progress
基金
江西省卫生健康委科技计划项目(202212237)。
